DENISE EPPERSON: Open Payments
NPI 1851440267 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 46 payments from 13 companies in 2025. Trend: 2023 $44 · 2024 $91 · 2025 $822
Food & beverage: $822
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $164 |
| Lundbeck LLC | 7 | $145 |
| Otsuka America Pharmaceutical, Inc. | 6 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $85 |
| Neurocrine BioSciences, Inc. | 4 | $70 |
| Tris Pharma Inc | 2 | $44 |
| ABBVIE INC. | 2 | $44 |
| Noven Therapeutics, LLC | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
Products named: REXULTI, CAPLYTA, ARISTADA, LYBALVI, INGREZZA, Dyanavel XR, VRAYLAR, Xelstrym.
Industry payments across KY — which companies pay providers there.
